151 related articles for article (PubMed ID: 31359126)
21. Potentialities of multi-b-values diffusion-weighted imaging for predicting efficacy of concurrent chemoradiotherapy in cervical cancer patients.
Liu B; Ma WL; Zhang GW; Sun Z; Wei MQ; Hou WH; Hou BX; Wei LC; Huan Y
BMC Med Imaging; 2020 Aug; 20(1):97. PubMed ID: 32799809
[TBL] [Abstract][Full Text] [Related]
22. Value of R2* obtained from T2*-weighted imaging in predicting the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy.
Li XS; Fan HX; Fang H; Song YL; Zhou CW
J Magn Reson Imaging; 2015 Sep; 42(3):681-8. PubMed ID: 25581675
[TBL] [Abstract][Full Text] [Related]
23. Association between IVIM parameters and treatment response in locally advanced squamous cell cervical cancer treated by chemoradiotherapy.
Perucho JAU; Wang M; Vardhanabhuti V; Tse KY; Chan KKL; Lee EYP
Eur Radiol; 2021 Oct; 31(10):7845-7854. PubMed ID: 33786654
[TBL] [Abstract][Full Text] [Related]
24. Tumor growth patterns on magnetic resonance imaging and treatment outcomes in patients with locally advanced cervical cancer treated with definitive radiotherapy.
Tsuruoka S; Kataoka M; Hamamoto Y; Tokumasu A; Uwatsu K; Kanzaki H; Takata N; Ishikawa H; Ouchi A; Mochizuki T
Int J Clin Oncol; 2019 Sep; 24(9):1119-1128. PubMed ID: 31079257
[TBL] [Abstract][Full Text] [Related]
25. Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer.
Kim JY; Byun SJ; Kim YS; Nam JH
Gynecol Oncol; 2017 Jan; 144(1):34-39. PubMed ID: 27789082
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort.
Endo D; Todo Y; Okamoto K; Minobe S; Kato H; Nishiyama N
J Gynecol Oncol; 2015 Jan; 26(1):12-8. PubMed ID: 25310853
[TBL] [Abstract][Full Text] [Related]
27. Prediction of pathologic responders to neoadjuvant chemoradiotherapy by diffusion-weighted magnetic resonance imaging in locally advanced esophageal squamous cell carcinoma: a prospective study.
Li QW; Qiu B; Wang B; Wang DL; Yin SH; Yang H; Liu JL; Fu JH; Liu MZ; Xie CM; Liu H
Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036528
[TBL] [Abstract][Full Text] [Related]
28. Histogram analysis of apparent diffusion coefficient for monitoring early response in patients with advanced cervical cancers undergoing concurrent chemo-radiotherapy.
Meng J; Zhu L; Zhu L; Ge Y; He J; Zhou Z; Yang X
Acta Radiol; 2017 Nov; 58(11):1400-1408. PubMed ID: 28273745
[TBL] [Abstract][Full Text] [Related]
29. Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer.
Ueno Y; Lisbona R; Tamada T; Alaref A; Sugimura K; Reinhold C
Br J Radiol; 2017 Jul; 90(1075):20170035. PubMed ID: 28508679
[TBL] [Abstract][Full Text] [Related]
30. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
[No Abstract] [Full Text] [Related]
31. Apparent diffusion coefficient histogram shape analysis for monitoring early response in patients with advanced cervical cancers undergoing concurrent chemo-radiotherapy.
Meng J; Zhu L; Zhu L; Wang H; Liu S; Yan J; Liu B; Guan Y; Ge Y; He J; Zhou Z; Yang X
Radiat Oncol; 2016 Oct; 11(1):141. PubMed ID: 27770816
[TBL] [Abstract][Full Text] [Related]
32. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI.
Nam H; Park W; Huh SJ; Bae DS; Kim BG; Lee JH; Lee JW; Lim DH; Han Y; Park HC; Ahn YC
Gynecol Oncol; 2007 Nov; 107(2):320-5. PubMed ID: 17675222
[TBL] [Abstract][Full Text] [Related]
33. Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery.
Yang J; Yang J; Cao D; Shen K; Ma J; Zhang F
J Gynecol Oncol; 2020 Mar; 31(2):e16. PubMed ID: 31912674
[TBL] [Abstract][Full Text] [Related]
34. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
[TBL] [Abstract][Full Text] [Related]
35. Value of blood oxygenation level-dependent MRI for predicting clinical outcomes in uterine cervical cancer treated with concurrent chemoradiotherapy.
Lee J; Kim CK; Gu KW; Park W
Eur Radiol; 2019 Nov; 29(11):6256-6265. PubMed ID: 31016443
[TBL] [Abstract][Full Text] [Related]
36. Characteristics, treatment patterns, and outcomes in patients with high-risk locally advanced cervical cancer.
Coutinho F; Gokhale M; Doran C; Monberg M; Yamada K; Chen L
Cancer Treat Res Commun; 2024; 39():100800. PubMed ID: 38430610
[TBL] [Abstract][Full Text] [Related]
37. Individualized pelvic lymphadenectomy should follow neoadjuvant concurrent chemoradiotherapy for locally advanced cervical cancer.
Wei LC; Li X; Zhang Y; Dang YZ; Li WW; Li JP; Zhao LN; Liu SJ; Li X; Shi M
Medicine (Baltimore); 2018 Apr; 97(14):e0331. PubMed ID: 29620659
[TBL] [Abstract][Full Text] [Related]
38. [Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].
Ma R; Zhang H; Zou L; Qu Y
Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):125-30. PubMed ID: 25877610
[TBL] [Abstract][Full Text] [Related]
39. Early response of patients undergoing concurrent chemoradiotherapy for cervical cancer: a comparison of PET/CT and MRI.
Lee JE; Huh SJ; Nam H; Ju SG
Ann Nucl Med; 2013 Jan; 27(1):37-45. PubMed ID: 23054833
[TBL] [Abstract][Full Text] [Related]
40. Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer.
Leseur J; Roman-Jimenez G; Devillers A; Ospina-Arango JD; Williaume D; Castelli J; Terve P; Lavoue V; Garin E; Lejeune F; Acosta O; De Crevoisier R
Radiother Oncol; 2016 Sep; 120(3):512-518. PubMed ID: 27569847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
